News
INCY
114.66
+0.80%
0.91
Incyte: New Catalysts Support Another Leg Higher
Seeking Alpha · 9h ago
Buy Rating Reaffirmed as Opzelura’s Global Opportunity Expands and DCF-Supported $140 Price Target Is Maintained
TipRanks · 11h ago
Weekly Report: what happened at INCY last week (0622-0626)?
Weekly Report · 11h ago
Barclays Keeps Their Buy Rating on Incyte (INCY)
TipRanks · 12h ago
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
Barchart · 16h ago
Notable healthcare headlines for the week: Merck, AbbVie, and Bayer in focus
Seeking Alpha · 1d ago
What Moved Markets This Week
Seeking Alpha · 2d ago
Accenture, Estée Lauder, Luckin, Incyte, BILL Trending
TipRanks · 2d ago
Incyte Corp. Stock Rises 5.8%, Outperforms Peers
Dow Jones · 3d ago
Incyte Is Maintained at Neutral by UBS
Dow Jones · 3d ago
UBS Maintains Neutral on Incyte, Raises Price Target to $113
Benzinga · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs 
Reuters · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber 
Reuters · 3d ago
Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know
TipRanks · 3d ago
Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms
Seeking Alpha · 3d ago
Acadia rises as EU backs Rett syndrome therapy
Seeking Alpha · 3d ago
Lilly, Incyte, CSL among winners of EU drug recommendations this week
Seeking Alpha · 3d ago
S&P 500 Movers: ON, INCY
NASDAQ · 3d ago
BUZZ-Incyte rises on positive EU panel opinion for eczema cream
Reuters · 3d ago
More
Webull provides a variety of real-time INCY stock news. You can receive the latest news about Incyte Corp through multiple platforms. This information may help you make smarter investment decisions.
About INCY
Incyte Corporation is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of therapeutics. The Company operates in three therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs. Its oncology franchise includes two approved products, PEMAZYRE (pemigatinib) and ZYNYZ (retifanlimab-dlwr), as well as several clinical development programs. Its Inflammation and Autoimmunity franchise is comprised of one approved product, OPZELURA (ruxolitinib) cream, with several clinical programs in development. The Company manages business activities on a consolidated basis through the development and commercialization of oncology and dermatology products.